AN NHS dentist at the centre of an HIV scare re-used gloves and didn’t clean instruments, we can reveal.
Clients were contacted last year over concerns about hygiene at two clinics run by Alan Morrison in Ayrshire.
Inspectors found staff had little or no training in cleaning instruments and used the same gloves for multiple patients.
51, was told to improve procedures but officials found the dentist –
once struck off for placing a patient’s life at risk – had given staff
instructions to re-use gloves and other equipment.
An increase in the
number of hepatitis C cases diagnosed in baby boomers since 2000 has
health officials urging people to get tested.
In 2000, Marathon
County had six cases of the liver disease, Portage County had 18 and
Wood County had one, according to figures from the Wisconsin Department
of Health Services. In 2012, the last year for which the agency had
numbers, Marathon County had 61 cases, Portage County had 14 cases and
Wood County had 30 cases.
In Wood County alone, there was a 26
percent increase in hepatitis C cases from 2010 to 2013, said Joanie
Kuennen, Wood County Health Department public health nurse.
(Reuters) – In the race to find a faster cure for hepatitis C, Bristol-Myers Squibb Co said it will test its experimental antiviral drug combination with Gilead Sciences Inc’s blockbuster drug Sovaldi, hoping to cut treatment time to four weeks.
disclosed plans for the exploratory 30-patient trial testing its
three-drug combination with Sovaldi in an interview with Reuters. Eric
Hughes, the leader of Bristol’s global hepatitis program, said the
details were due to be posted on the clinicaltrials.gov website next
Bristol’s plan essentially revives an effort to
test its drugs in combination with Sovaldi. It previously tested a
single compound with Sovaldi, achieving cure rates close to 100 percent
in 12 weeks. But Gilead scrapped further testing in 2012, as it
preferred to develop its own combination without a partner.
London will soon join several other Canadian cities in providing drug
users with access to free crack pipes and the move has the city’s Chief
of Police expressing concern.
The proposal received unanimous support at Thursday night’s meeting of the Middlesex-London Board of Health.
Supporters of the plan argue limited availability of safe smoking
supplies makes a user more likely to share their paraphernalia,
increasing the risk of contracting diseases like HIV or Hepatitis C.
While London Police Chief Brad Duncan supports that aspect of the plan,
he has some reservations.
Ferozsons Laboratories Limited has entered into an agreement with Gilead
Sciences to be its exclusive branded medicines business partner for
Pakistan, officials said on Thursday.
agreement, Ferozsons will market and distribute certain Gilead
medications for the treatment of chronic Hepatitis-C; HIV and chronic
Hepatitis-B virus (HBV) infection in Pakistan, the officials said.
Khalid Waheed, president of Ferozsons Laboratories Limited, said: “The
agreement is a very important milestone for the company but more
significantly it also marks a paradigm shift in the treatment landscape
for diseases such as Hepatitis C, which affects over 10 million people
in the country. We look forward to bringing these new innovations to
patients in Pakistan.”
Stribild and Sovaldi are pending
registration in Pakistan. The registration application for Sovaldi was
submitted in May with the request for an accelerated review on the basis
of medical needs, he said
The Centers for Disease Control and Prevention has launched a new
pilot program that leverages health IT and telemedicine to combat the
growing problem of hepatitis C virus (HCV) infection in the United
Called Project ECHO, CDC has funded weekly videoconferencing programs
in Arizona and Utah to boost primary care capacity for treatment of HCV
in areas of the country that have a shortage of specialists. To date,
66 primary care clinicians, predominantly from rural settings, have
received training through the program and 46 percent of patients have
received antiviral treatment.
In concert with the pilot program, the Office of the National
Coordinator for Health IT–working with the American Medical
Association–is creating new HCV clinical quality measures and clinical
decision support tools to improve screening and referral for treatment.
The project is identifying CQMs for testing, linking them to care,
validating the measures, and developing corresponding CDS tools to
provide up-to-date guidelines and other information to members of the
A story recently appeared in the Canadian Journal of Gastroenterology
and Hepatology that health authorities in Canada cannot ignore.
The authors of this article (Burden of Disease and Cost of Chronic Hepatitis C Virus Infection in Canada)
used projections based on the natural history of hepatitis C to try to
determine how much the disease is currently costing and what it will
cost in the future as the infected population ages and starts to develop
the complications of cirrhosis, liver failure and liver cancer. The
results are startling.
The health-care costs related to hepatitis C are huge and will continue
to grow. We currently spend about $161.4 million annually to treat the
consequences of hepatitis C. However, the new data indicate this will
rise to $258.4 million per year in 2032. During the next 20 years,
32,000 people will die prematurely from hepatitis C, an increase of 160
per cent from today’s rates. There will be a 205-per-cent increase in
liver cancer related to hepatitis C.